NEW YORK (GenomeWeb News) – Celsis In Vitro Technologies, a division of life science products and lab services firm Celsis International, today announced that it is collaborating with Promega on ADME-Tox assays for hepatocytes.

Baltimore-based Celsis IVT said that it will provide pre-qualified lots of its cryopreserved hepatocytes for use with Promega's bioluminescent ADME-Tox assays, including those used to study cytochrome P450 gene induction and inhibition and its GSH-Glo Glutathione assay for investigating mechanisms of hepatoxicity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.